Skip to main content
SpringerLink
Log in

Glutamate Receptor Antagonists and the Treatment of Neurological Disorders

  • Chapter
Neurochemical Aspects of Excitotoxicity

  • 562 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Albers G. W., Atkinson R. P., Kelley R. E., and Rosenbaum D. M. (1995). Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke 26:254–258.

    CAS  Google Scholar 

  • Albers G. W., Goldstein L. B., Hall D., and Lesko L. M. (2001). Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. J. Am. Med. Assoc. 286:2673–2682.

    Article  CAS  Google Scholar 

  • Bordi F., Pietra C., Ziviani L., and Reggiani A. (1997). The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp. Neurol. 145:425–433.

    Article  PubMed  CAS  Google Scholar 

  • Buisson B. and Bertrand D. (1998). Open-channel blockers at the human α4β2 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53:555–563.

    PubMed  CAS  Google Scholar 

  • Chadwick D. W., Betts T. A., Boddie H. G., Crawford P. M., Lindstrom P., Newman P. K., Soryal I., Wroe S., and Holdich T. A. (2002). Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. Seizure. 11:114–123.

    Article  PubMed  CAS  Google Scholar 

  • Chen H. S. and Lipton S. A. (2006). The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 97:1611–1626.

    Article  PubMed  CAS  Google Scholar 

  • Choi D. W. (1990). Cerebral hypoxia: some new approaches and unanswered questions. J. Neurosci. 10:2493–2501.

    PubMed  CAS  Google Scholar 

  • Choi Y. B., Tenneti L., Le D. A., Ortiz J., Bai G., Chen H. S., and Lipton S. A. (2000). Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat. Neurosci. 3:15–21.

    Article  PubMed  CAS  Google Scholar 

  • Coderre T. J. (1993). The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in rats. Mol. Neurobiol 7:229–246.

    PubMed  CAS  Google Scholar 

  • Davis M., Mendelow A. D., Perry R. H., Chambers I. R., and James O. F. (1995). Experimental stroke and neuroprotection in the aging rat brain. Stroke 26:1072–1078.

    PubMed  CAS  Google Scholar 

  • Davis S. M., Lees K. R., Albers G. W., Diener H. C., Markabi S., Karlsson G., and Norris J. (2000). Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31:347–354.

    PubMed  CAS  Google Scholar 

  • Dickenson A. H. (1990). A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol. Sci. 11:307–309.

    Article  PubMed  CAS  Google Scholar 

  • Doraiswamy P. M. (2002). Non-cholinergic strategies for treating and preventing Alzheimer’s disease. CNS Drugs 16:811–824.

    Article  PubMed  CAS  Google Scholar 

  • Dyker A. G., Edwards K. R., Fayad P. B., Hormes J. T., and Lees K. R. (1999). Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. Stroke 30:2038–2042.

    PubMed  CAS  Google Scholar 

  • Dyker A. G. and Lees K. R. (1999). Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke 30: 1796–1801.

    PubMed  CAS  Google Scholar 

  • Ellison G. (1994). Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. NeuroReport 5:2688–2692.

    Article  PubMed  CAS  Google Scholar 

  • Ellison G. (1995). The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Rev. 20:250–267.

    Article  PubMed  CAS  Google Scholar 

  • Endres M., Fink K., Zhu J., Stagliano N. E., Bondada V., Geddes J. W., Azuma T., Mattson M. P., Kwiatkowski D. J., and Moskowitz M. A. (1999). Neuroprotective effects of gelsolin during murine stroke. J. Clin. Invest 103:347–354.

    Article  PubMed  CAS  Google Scholar 

  • Fagg G. E. and Baud J. (1988). Characterization of NMDA receptor-ionophore complexes in the brain. In: Lodge D. (ed.), Excitatory Amino Acids in Health and Disease. John Wiley & Sons, New York, pp. 63–90.

    Google Scholar 

  • Farin A. and Marshall L. F. (2004). Lessons from epidemiologic studies in clinical trials of traumatic brain injury. Acta Neurochir. Suppl 89:101–107.

    PubMed  CAS  Google Scholar 

  • Farooqui A. A. and Horrocks L. A. (1994). Excitotoxicity and neurological disorders: involvement of membrane phospholipids. Int. Rev. Neurobiol. 36:267–323.

    PubMed  CAS  Google Scholar 

  • Farooqui A. A. and Horrocks L. A. (2007a). Glutamate and cytokine-mediated alterations of phospholipids in head injury and spinal cord trauma. In: Banik N. (ed.), Brain and Spinal Cord Trauma. Handbook of Neurochemistry. Lajtha, A. (ed.). Springer, New York.

    Google Scholar 

  • Farooqui A. A. and Horrocks L. A. (2007b). Glycerophospholipids in the Brain: Phospholipases A 2 in Neurological Disorders, pp. 1–394. Springer, New York.

    Google Scholar 

  • Ferrer-Montiel A. V., Sun W., and Montal M. (1995). Molecular design of the N-methyl-D-aspartate receptor binding site for phencyclidine and dizolcipine. Proc. Natl. Acad. Sci. U.S.A 92:8021–8025.

    Article  PubMed  CAS  Google Scholar 

  • Gallagher M. J., Huang H., Pritchett D. B., and Lynch D. R. (1996). Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem. 271:9603–9611.

    Article  PubMed  CAS  Google Scholar 

  • Gilron I. and Max M. B. (2005). Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev. Neurother. 5:823–830.

    Article  PubMed  CAS  Google Scholar 

  • Gilron I., Max M. B., Lee G., Booher S. L., Sang C. N., Chappell A. S., and Dionne R. A. (2000). Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin. Pharmacol. Ther. 68:320–327.

    Article  PubMed  CAS  Google Scholar 

  • Grant G., Cadossi R., and Steinberg G. (1994). Protection against focal cerebral ischemia following exposure to a pulsed electromagnetic field. Bioelectromagnetics 15:205–216.

    Article  PubMed  CAS  Google Scholar 

  • Grossberg G. T., Edwards K. R., and Zhao Q. (2006). Rationale for combination therapy with galantamine and memantine in Alzheimer’s disease. J. Clin. Pharmacol. 46:17S–26S.

    Article  PubMed  CAS  Google Scholar 

  • Grotta J., Clark W., Coull B., Pettigrew L. C., Mackay B., Goldstein L. B., Meissner I., Murphy D., and LaRue L. (1995). Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke 26:602–605.

    PubMed  CAS  Google Scholar 

  • Grotta J. C., Picone C. M., Ostrow P. T., Strong R. A., Earls R. M., Yao L. P., Rhoades H. M., and Dedman J. R. (1990). CGS-19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann. Neurol. 27:612–619.

    Article  PubMed  CAS  Google Scholar 

  • Gustafson I., Westerberg E., and Wieloch T. (1990). Protection against ischemia-induced neuronal damage by the alpha 2-adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J. Cereb. Blood Flow Metab 10:885–894.

    PubMed  CAS  Google Scholar 

  • Helfaer M. A., Ichord R. N., Martin L. J., Hurn P. D., Castro A., and Traystman R. J. (1998). Treatment with the competitive NMDA antagonist GPI 3000 does not improve outcome after cardiac arrest in dogs. Stroke 29:824–829.

    PubMed  CAS  Google Scholar 

  • Hewitt D. J. (2000). The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin. J. Pain 16:S73–S79.

    Article  PubMed  CAS  Google Scholar 

  • Jewett D. C., Butelman E. R., and Woods J. H. (1996). Nitric oxide synthase inhibitors produce phencyclidine-like behavioral effects in pigeons. Brain Res. 715:25–31.

    Article  PubMed  CAS  Google Scholar 

  • Kawasaki-Yatsugi S., Ichiki C., Yatsugi S., Takahashi M., Shimizu-Sasamata M., Yamaguchi T., and Minematsu K. (2000). Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model. Neuropharmacology 39:211–217.

    Article  PubMed  CAS  Google Scholar 

  • Kemp J. A. and McKernan R. M. (2002). NMDA receptor pathways as drug targets. Nat. Neurosci. 5:1039–1042.

    Article  PubMed  CAS  Google Scholar 

  • Kilpatrick G. J. and Tilbrook G. S. (2002). Memantine. Merz. Curr. Opin. Investig. Drugs 3:798–806.

    CAS  Google Scholar 

  • Klamer D., Zhang J., Engel J. A., and Svensson L. (2005). Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat. Behav. Brain Res. 159:95–103.

    Article  PubMed  CAS  Google Scholar 

  • Klepstad P. and Borchgrevink P. C. (1997). Four years’ treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol. Scand. 41:422–426.

    PubMed  CAS  Google Scholar 

  • Koch H. J., Uyanik G., and Fischer-Barnicol D. (2005). Memantine: a therapeutic approach in treating Alzheimer’s and vascular dementia. Curr. Drug Targets CNS Neurol. Disord. 4: 499–506.

    Google Scholar 

  • Kohl B. K. and Dannhardt G. (2001). The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr. Med. Chem. 8:1275–1289.

    PubMed  CAS  Google Scholar 

  • Kornhuber J. and Weller M. (1997). Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry 41:135–144.

    Article  PubMed  CAS  Google Scholar 

  • Koroshetz W. J. and Moskowitz M. A. (1996). Emerging treatments for stroke in humans. Trends Pharmacol. Sci. 17:227–233.

    Article  PubMed  CAS  Google Scholar 

  • Labiche L. A. and Grotta J. C. (2004). Clinical trials for cytoprotection in stroke. NeuroRx. 1:46–70.

    Article  PubMed  Google Scholar 

  • Lee S. T., Chu K., Park J. E., Kang L., Ko S. Y., Jung K. H., and Kim M. (2006). Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington’s disease. Brain Res. 1118:199–207.

    Article  PubMed  CAS  Google Scholar 

  • Lees K. R. (1997). Cerestat and other NMDA antagonists in ischemic stroke. Neurology 49:S66–S69.

    PubMed  CAS  Google Scholar 

  • Lees K. R., Asplund K., Carolei A., Davis S. M., Diener H. C., Kaste M., Orgogozo J. M., and Whitehead J. (2000). Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 355:1949–1954.

    CAS  Google Scholar 

  • Lipton S. A. (1993). Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 16:527–532.

    Article  PubMed  CAS  Google Scholar 

  • Lipton S. A., Choi Y. B., Sucher N. J., and Chen H. S. (1998). Neuroprotective versus neurodestructive effects of NO-related species. BioFactors 8:33–40.

    PubMed  CAS  Google Scholar 

  • Lipton S. A., Choi Y. B., Takahashi H., Zhang D., Li W., Godzik A., and Bankston L. A. (2002). Cysteine regulation of protein function–as exemplified by NMDA-receptor modulation. Trends Neurosci. 25:474–480.

    Article  PubMed  CAS  Google Scholar 

  • Lipton S. A. and Rosenberg P. A. (1994). Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330:613–622.

    Article  PubMed  CAS  Google Scholar 

  • Lu B. (2003). BDNF and activity-dependent synaptic modulation. Learn. Mem. 10:86–98.

    Article  PubMed  Google Scholar 

  • Marvanova M., Lakso M., Pirhonen J., Nawa H., Wong G., and Castren E. (2001). The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol. Cell Neurosci. 18:247–258.

    Article  PubMed  CAS  Google Scholar 

  • Max M. B. and Hagen N. A. (2000). Do changes in brain sodium channels cause central pain? Neurology 54:544–545.

    PubMed  CAS  Google Scholar 

  • Minematsu K., Fisher M., Li L., Davis M. A., Knapp A. G., Cotter R. E., McBurney R. N., and Sotak C. H. (1993). Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology 43:397–403.

    PubMed  CAS  Google Scholar 

  • Mori H., Masaki H., Yamakura T., and Mishina M. (1992). Identification by mutagenesis of a Mg2+-block site of the NMDA receptor channel. Nature 358:673–675.

    Article  PubMed  CAS  Google Scholar 

  • Morris G. F., Bullock R., Marshall S. B., Marmarou A., Maas A., and Marshall L. F. (1999). Failure of the competitive N-methyl-D-aspartate antagonist selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J. Neurosurg. 91:737–743.

    PubMed  CAS  Google Scholar 

  • Muir K. W. (2006). Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr. Opin. Pharmacol. 6:53–60.

    Article  PubMed  CAS  Google Scholar 

  • Nelson K. A., Park K. M., Robinovitz E., Tsigos C., and Max M. B. (1997). High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 48:1212–1218.

    PubMed  CAS  Google Scholar 

  • Ogren S. O. and Goldstein M. (1994). Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 11:167–177.

    Article  PubMed  CAS  Google Scholar 

  • Osawa Y. and Davila J. C. (1993). Phencyclidine, a psychotomimetic agent and drug of abuse, is a suicide inhibitor of brain nitric oxide synthase. Biochem. Biophys. Res. Commun. 194:1435–1439.

    Article  PubMed  CAS  Google Scholar 

  • Palmer G. C. (2001). Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr. Drug Targets 2:241–271.

    Article  PubMed  CAS  Google Scholar 

  • Parton A., Coulthard E., and Husain M. (2005). Neuropharmacological modulation of cognitive deficits after brain damage. Curr. Opin. Neurol. 18:675–680.

    Article  PubMed  Google Scholar 

  • Paul C. and Bolton C. (2002). Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. J. Pharmacol. Exp. Ther. 302:50–57.

    Article  PubMed  CAS  Google Scholar 

  • Pettegrew J. W., Klunk W. E., Kanal E., Panchalingam K., and McClure R. J. (1995). Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol. Aging 16:973–975.

    Article  PubMed  CAS  Google Scholar 

  • Planells-Cases R., Lerma J., and Ferrer-Montiel A. (2006). Pharmacological intervention at ionotropic glutamate receptor complexes. Curr. Pharm. Des 12:3583–3596.

    Article  PubMed  CAS  Google Scholar 

  • Rajdev S., Fix A. S., and Sharp F. R. (1998). Acute phencyclidine neurotoxicity in rat forebrain: induction of haem oxygenase-1 and attenuation by the antioxidant dimethylthiourea. Eur. J. Neurosci. 10:3840–3852.

    Article  PubMed  CAS  Google Scholar 

  • Rammes G., Rupprecht R., Ferrari U., Zieglgänsberger W., and Parsons C. G. (2001). The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci. Lett. 306:81–84.

    Google Scholar 

  • Ratan R. R., Murphy T. H., and Baraban J. M. (1994). Oxidative stress induces apoptosis in embryonic cortical neurons. J. Neurochem. 62:376–379.

    Article  PubMed  CAS  Google Scholar 

  • Reeker W., Werner C., Mollenberg O., Mielke L., and Kochs E. (2000). High-dose S(+)-ketamine improves neurological outcome following incomplete cerebral ischemia in rats. Can. J. Anaesth. 47:572–578.

    PubMed  CAS  Google Scholar 

  • Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H. J. (2003). Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 348:1333–1341.

    Article  PubMed  CAS  Google Scholar 

  • Rogawski M. A. and Wenk G. L. (2003). The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 9:275–308.

    Article  PubMed  CAS  Google Scholar 

  • Sacco R. L., DeRosa J. T., Haley E. C., Jr., Levin B., Ordronneau P., Phillips S. J., Rundek T., Snipes R. G., and Thompson J. L. (2001). Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. J. Am. Med. Assoc. 285:1719–1728.

    Article  CAS  Google Scholar 

  • Sang C. N., Booher S., Gilron I., Parada S., and Max M. B. (2002). Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 96:1053–1061.

    Article  PubMed  CAS  Google Scholar 

  • Sarraf-Yazdi S., Sheng H., Miura Y., McFarlane C., Dexter F., Pearlstein R., and Warner D. S. (1998). Relative neuroprotective effects of dizocilpine and isoflurane during focal cerebral ischemia in the rat. Anesth. Analg. 87:72–78.

    Article  PubMed  CAS  Google Scholar 

  • Schabitz W. R., Li F., and Fisher M. (2000). The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. Stroke 31:1709–1714.

    PubMed  CAS  Google Scholar 

  • Schehr R. S. (1996). New treatments for acute stroke. Nat. Biotechnol. 14:1549–1554.

    Article  PubMed  CAS  Google Scholar 

  • Schiefermeier M. and Yavin E. (2002). n-3 Deficient and docosahexaenoic acid-enriched diets during critical periods of the developing prenatal rat brain. J. Lipid Res. 43:124–131.

    PubMed  CAS  Google Scholar 

  • Schmitt F., Ryan M., and Cooper G. (2007). A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer’s disease. Expert Opin. Drug Metab Toxicol. 3:135–141.

    Article  PubMed  CAS  Google Scholar 

  • Shimizu-Sasamata M., Kawasaki-Yatsugi S., Okada M., Sakamoto S., Yatsugi S., Togami J., Hatanaka K., Ohmori J., Koshiya K., Usuda S., and Murase K. (1996). YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist. J. Pharmacol. Exp. Ther. 276:84–92.

    PubMed  CAS  Google Scholar 

  • Shohami E., Novikov M., and Mechoulam R. (1993). A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J. Neurotrauma 10:109–119.

    PubMed  CAS  Google Scholar 

  • Smith M., Wells J., and Borrie M. (2006). Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 20:133–137.

    Article  PubMed  CAS  Google Scholar 

  • Sonkusare S. K., Kaul C. L., and Ramarao P. (2005). Dementia of Alzheimer’s disease and other neurodegenerative disorders–memantine, a new hope. Pharmacol. Res 51:1–17.

    PubMed  CAS  Google Scholar 

  • Suzuki M., Sasamata M., and Miyata K. (2003). Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model. Brain Res. 959:169–172.

    Article  PubMed  CAS  Google Scholar 

  • Tanovic A. and Alfaro V. (2006). Neuroprotecciòn con memantina (antagonista no competitivo del receptor NMDA-glutamato) frente a la excitotoxicidad asociada al glutamato en la enfermedad de Alzheimer y en la demencia vascular [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer’s disease and vascular dementia]. Rev. Neurol. 42:607–616.

    PubMed  CAS  Google Scholar 

  • Tariot P. N., Farlow M. R., Grossberg G. T., Graham S. M., McDonald S., and Gergel I. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J. Am. Med. Assoc. 291:317–324.

    Article  CAS  Google Scholar 

  • Teramoto S., Matsuse T., and Ouchi T. (1999). Amantadine and pneumonia in elderly stroke patients. Lancet 353:2156–2157.

    Article  PubMed  CAS  Google Scholar 

  • The STIPAS Investigators (1994). Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 25:418–423.

    Google Scholar 

  • Wang K. K., Larner S. F., Robinson G., and Hayes R. L. (2006a). Neuroprotection targets after traumatic brain injury. Curr. Opin. Neurol. 19:514–519.

    Article  CAS  Google Scholar 

  • Wang Y., Eu J., Washburn M., Gong T., Chen H. S., James W. L., Lipton S. A., Stamler J. S., Went G. T., and Porter S. (2006b). The pharmacology of aminoadamantane nitrates. Curr. Alzheimer Res. 3:201–204.

    Article  Google Scholar 

  • Weber C. (1998). [NMDA-receptor antagonist in pain therapy]. Anasthesiol. Intensivmed. Notfallmed. Schmerzther. 33:475–483.

    PubMed  CAS  Google Scholar 

  • Wenk G. L. (2006). Neuropathologic changes in Alzheimer’s disease: potential targets for treatment. J. Clin. Psychiatry 67(Suppl 3):3–7.

    PubMed  CAS  Google Scholar 

  • Wu J., Tang T., and Bezprozvanny I. (2006). Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington’s disease. Neurosci. Lett. 407:219–223.

    Article  PubMed  CAS  Google Scholar 

  • Yamakura T. and Shimoji K. (1999). Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog. Neurobiol. 59:279–298.

    Article  PubMed  CAS  Google Scholar 

  • Yen W., Williamson J., Bertram E. H., and Kapur J. (2004). A comparison of three NMDA receptor antagonists in the treatment of prolonged status epilepticus. Epilepsy Res. 59:43–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Cellular Biochemistry, The Ohio State University, 3120 Herrick Road, Columbus, Ohio, USA

    Akhlaq A. Farooqui

  2. Department of Anatomy, Faculty of Medicine, National University of Singapore, Singapore

    Wei-Yi Ong

  3. The Ohio State University, Columbus, Ohio

    Lloyd A. Horrocks

Authors
  1. Akhlaq A. Farooqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei-Yi Ong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lloyd A. Horrocks
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Farooqui, A.A., Ong, WY., Horrocks, L.A. (2008). Glutamate Receptor Antagonists and the Treatment of Neurological Disorders. In: Neurochemical Aspects of Excitotoxicity. Springer, New York, NY. https://doi.org/10.1007/978-0-387-73023-3_10

Download citation

Publish with us

Policies and ethics

Search

Navigation